<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hugo López-Pelayo</style></author><author><style face="normal" font="default" size="100%">Santiago Madero</style></author><author><style face="normal" font="default" size="100%">L. Gremeaux</style></author><author><style face="normal" font="default" size="100%">Sanna Rönkä</style></author><author><style face="normal" font="default" size="100%">João Matias</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthetic Cannabinoids and Cannabis: How the Patterns of Use Differ: Results from the European Web Survey on Drugs</style></title><secondary-title><style face="normal" font="default" size="100%">International Journal of Mental Health and Addiction</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">cannabis</style></keyword><keyword><style  face="normal" font="default" size="100%">new psychoactive substances</style></keyword><keyword><style  face="normal" font="default" size="100%">Synthetic cannabinoids</style></keyword><keyword><style  face="normal" font="default" size="100%">Web Survey on Drugs</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar-10-2022</style></date></pub-dates></dates><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;The aim of the current study is to assess if the patterns of use, socio-demographic characteristics,&lt;br&gt;
and use of other drugs differ among people who only use cannabis and those that&lt;br&gt;
use synthetic cannabinoids. Data from the second wave of the European Web Survey on&lt;br&gt;
Drugs, a web-based cross-sectional survey from 10 different European countries including&lt;br&gt;
individuals aged 18 and over (n = 37,109). Participation was anonymous, self-selecting,&lt;br&gt;
and voluntary. Cannabinoid exposure was taken as the dependent variable and categorized&lt;br&gt;
into the four following variables: (1) neither last year use of cannabis nor of synthetic&lt;br&gt;
cannabinoids (SC) independently of lifetime use, (2) cannabis use, (3) synthetic cannabinoids&lt;br&gt;
use, and (4) use of both, in the last 12 months. Independent variables included&lt;br&gt;
socio-demographic data, other drug use in the last month, and patterns of cannabis use.&lt;br&gt;
The use of SC was associated with higher odd of polysubstance use in the last year (OR&lt;br&gt;
2.17; 95%CI 1.27–3.72) and use of other drugs during the last month. Low income (OR&lt;br&gt;
2.34; 95%CI 1.20–4.58) and unemployment (OR 3.02; 95%CI 1.34–6.83) were related to&lt;br&gt;
SC use alone and cannabis plus SC use (OR 1.53; 95%CI 1.13–2.05) (OR 4.12; 95%CI&lt;br&gt;
3.45–4.91). Social vulnerabilities were associated with the use of cannabis in the last year,&lt;br&gt;
but more markedly with synthetic cannabinoids use. Those who used synthetic cannabinoids&lt;br&gt;
reported using other drugs more often than those who used or did not use cannabis.&lt;br&gt;
The findings highlight the importance of social vulnerabilities and poly-drug use when&lt;br&gt;
assessing the use of new psychoactive substances such as SC and how these differ when&lt;br&gt;
compared to cannabis.&lt;/p&gt;
</style></abstract></record></records></xml>